Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Arcutis (Nasdaq: ARQT) announced management will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) announced management will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company will host a Fireside Chat on March 2, 2026 at 1:50 p.m. ET.
The live webcast is available via the company Events page and a replay will remain accessible on the Arcutis website for 180 days following the conference.
Details
News Market Reaction – ARQT
On Mar 2, the first trading day after this news, ARQT closed 8.19% below the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Conference dates
- March 2–4, 2026
- TD Cowen 46th Annual Health Care Conference in Boston
- Fireside chat time
- 1:50 p.m. ET, March 2, 2026
- Scheduled Arcutis management presentation slot
- Webcast replay duration
- 180 days
- Replay availability on Arcutis website following the conference
Historical Context
-
Profitable Q4 2025, strong ZORYVE revenue growth, raised 2026 sales guidance.
-
Max Homa joins seborrheic dermatitis campaign highlighting ZORYVE foam benefits.
-
Equity inducement RSU grants to new hires under 2022 Inducement Plan.
-
Positive topline INTEGUMENT-INFANT Phase 2 results for ZORYVE cream 0.05%.
-
Termination of Kowa promotion with Arcutis retaining promotion and guidance unchanged.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.
Details for the Company’s participation are as follows:
Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.